Kane Biotech Inc Total Liabilities
Kane Biotech Inc total liabilities. Based on the latest financial reports, Kane Biotech Inc (KNE) has total liabilities worth CA$3.48 Million CAD (≈ $2.52 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Kane Biotech Inc (KNE) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Kane Biotech Inc (2003–2025)
Total liabilities of Kane Biotech Inc from 2003 to 2025. This chart illustrates how Kane Biotech Inc's total liabilities have evolved over time, based on quarterly financial data.
Kane Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Kane Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Strategem Capital Corp
V:SGE
|
Canada | CA$54.00K |
|
CARLSON INV. ZY 13
F:2HB
|
Germany | €1.12 Million |
|
UNITH LTD.
F:CM30
|
Germany | €1.61 Million |
|
Carmell Therapeutics Corporation
NASDAQ:CTCX
|
USA | $7.14 Million |
|
Resources & Energy Group Ltd
AU:REZ
|
Australia | AU$1.61 Million |
|
OLB Group Inc
NASDAQ:OLB
|
USA | $6.80 Million |
|
Acurx Pharmaceuticals LLC
NASDAQ:ACXP
|
USA | $2.83 Million |
|
DSS Inc
NYSE MKT:DSS
|
USA | $66.02 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Kane Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kane Biotech Inc assets under control.
Liquidity & Leverage Metrics
Kane Biotech Inc Total Liabilities Ratios Explained
Kane Biotech Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kane Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kane Biotech Inc (2003–2025)
The table below shows the annual total liabilities of Kane Biotech Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$3.48 Million ≈ $2.52 Million |
-15.59% |
| 2024-12-31 | CA$4.12 Million ≈ $2.98 Million |
-70.74% |
| 2023-12-31 | CA$14.09 Million ≈ $10.19 Million |
+44.40% |
| 2022-12-31 | CA$9.76 Million ≈ $7.06 Million |
+26.70% |
| 2021-12-31 | CA$7.70 Million ≈ $5.57 Million |
+94.43% |
| 2020-12-31 | CA$3.96 Million ≈ $2.87 Million |
+106.42% |
| 2019-12-31 | CA$1.92 Million ≈ $1.39 Million |
-24.48% |
| 2018-12-31 | CA$2.54 Million ≈ $1.84 Million |
+285.53% |
| 2017-12-31 | CA$659.03K ≈ $476.74K |
-15.91% |
| 2016-12-31 | CA$783.72K ≈ $566.93K |
+13.11% |
| 2015-12-31 | CA$692.86K ≈ $501.21K |
+4.27% |
| 2014-12-31 | CA$664.51K ≈ $480.70K |
+10.69% |
| 2013-12-31 | CA$600.31K ≈ $434.26K |
+239.68% |
| 2012-12-31 | CA$176.73K ≈ $127.84K |
+90.59% |
| 2011-12-31 | CA$92.72K ≈ $67.08K |
+2.18% |
| 2010-12-31 | CA$90.75K ≈ $65.65K |
+32.25% |
| 2009-12-31 | CA$68.62K ≈ $49.64K |
-13.76% |
| 2008-12-31 | CA$79.56K ≈ $57.55K |
-9.44% |
| 2007-12-31 | CA$87.86K ≈ $63.56K |
-5.36% |
| 2006-12-31 | CA$92.83K ≈ $67.16K |
-31.04% |
| 2005-12-31 | CA$134.62K ≈ $97.38K |
+35.00% |
| 2004-12-31 | CA$99.72K ≈ $72.14K |
+74.88% |
| 2003-12-31 | CA$57.02K ≈ $41.25K |
-- |
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the … Read more